title: Pharmacogenomic testing: relevance in medical practice: why drugs work in some patients but not in others.
abstract: Genetics may account for much of the variability in our patients' responses to drug therapies. This article offers the clinician an up-to-date overview of pharmacogenomic testing, discussing implications and limitations of emerging validated tests relevant to the use of warfarin (Coumadin), clopidogrel (Plavix), statins, tamoxifen (Nolvadex), codeine, and psychotropic drugs. It also discusses the future role of pharmacogenomic testing in medicine.
authors: Department of Pharmacology, Division of Clinical Trials, College of Medicine, The Ohio State University, Columbus, USA. joseph.kitzmiller@osumc.edu
authors: Joseph P
authors: JP
authors: Kitzmiller
authors: David K
authors: DK
authors: Groen
authors: Mitch A
authors: MA
authors: Phelps
authors: Wolfgang
authors: W
authors: Sadee
mesh_terms: D000077144:Clopidogrel; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology; D010597:Pharmacogenetics / Q000379:methods*; D011619:Psychotropic Drugs / Q000494:pharmacology; D013629:Tamoxifen / Q000494:pharmacology; D013988:Ticlopidine / Q000031:analogs & derivatives / Q000494:pharmacology; D014859:Warfarin / Q000494:pharmacology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011619:Psychotropic Drugs; D013629:Tamoxifen; D014859:Warfarin; D003577:Cytochrome P-450 Enzyme System; D000077144:Clopidogrel; D013988:Ticlopidine